Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25485645 | 0.90 | SCD5 (0.48) | USP2SMN1; SMN2HPGDGPR119SCD5 | |
| SCHEMBL16580040 | 0.89 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL346995 | 0.85 | USP2 (0.56) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL24906944 | 0.85 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL21358370 | 0.82 | USP2 (0.44) | USP2SMN1; SMN2HPGDEPHX2SCD5 | |
| SCHEMBL20937613 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL933177 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL15769706 | 0.81 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL20937760 | 0.81 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL1779347 | 0.81 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12109203-B2 | Substituted oxazolidinones for the treatment of mammalian infections | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-10-08 | — | — | US | disclosed |
| WO-2020021468-A1 | SUBSTITUTED OXAZOLIDINONES FOR THE TREATMENT OF MAMMALIAN INFECTIONS | CADILA HEALTHCARE LIMITED (IN) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020021468-A1 | SUBSTITUTED OXAZOLIDINONES FOR THE TREATMENT OF MAMMALIAN INFECTIONS | CADILA HEALTHCARE LIMITED (IN) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12109203-B2 | Substituted oxazolidinones for the treatment of mammalian infections | OXA1L, IL4I1, PEPD | USP2 4551/4885SMN1; SMN2 2025/4885HPGD 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.